Search Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologySarcomasSarcomas (ped.)DiseaseLiver Sarcoma UndifferentiatedRhabdomyosarcomaSoft Tissue SarcomaSubgroupALK+Alveolar Soft Tissue SarcomaAngiosarcomaDermatofibrosarcoma protuberansFibromatosis, aggressiveHemangiopericytomaLeiomyosarcomaLeiomyosarcoma, uterineLiposarcomaLiposarcoma, dedifferentiatedMyofibroblast Tumor, inflammatoryRhabdomyosarcomaSolitary Fibrous TumorSynovial SarcomaICD10C49.-MeSHFibromatosis, AggressiveHemangiosarcomaLeiomyosarcomaNeoplasms, Connective and Soft TissueRhabdomyosarcoma, EmbryonalSarcomaUterine NeoplasmsSequenceGEMC900/DOCE75, Soft Tissue Sarcoma, adj., A (PID1945) -|- DOXO60, B (PID1946)LMS-04: DOXO60/TRAB1.1, Soft Tissue Sarcoma (PID2210) -|- TRAB1.1, Maint. (PID2219)OLAR15/DOXO75, Soft Tissue Sarcoma, C1 (PID845) -|- C2-4 (PID846) -|- C5-8 (PID851) -|- Maint. (PID847)PACL90/BEVA15, Soft Tissue Sarcoma (PID1827) -|- BEVA15 (PID1826)PACL200/BEVA15,Soft Tissue Sarcoma (PID1828) -|- BEVA15 (PID1826)VAIA III, Soft Tissue SarcomaVIT-0910: VIT (TMZL125/VNCR2/IRIN50), Soft Tissue Sarcoma, C1 (PID2255) -|- VIT (TMZL150/VNCR2/IRIN50), C2-12 (PID2256).ChemotherapyChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTemozolomideTrabectedinVinblastineVincristineVinorelbineChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTemozolomideTrabectedinVinblastineVincristineVinorelbineChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTemozolomideTrabectedinVinblastineVincristineVinorelbineChemo-substanceAtezolizumabAxitinibBevacizumabCabazitaxelCrizotinibCyclophosphamideDacarbazineDactinomycinDocetaxelDoxorubicinDoxorubicin pegylated liposomalEpirubicinEribulinGemcitabineIfosfamideImatinibIrinotecanMesnaMethotrexateOlaratumabPaclitaxelPazopanibPembrolizumabSelinexorSorafenibSunitinibTemozolomideTrabectedinVinblastineVincristineVinorelbineNo. Substances123 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDexrazoxaneDimetindenFamotidineFosaprepitantGranisetronMesnaPegfilgrastimPyridoxineNo. Substances1234568Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseneoadjuvantneoadjuvant / adjuvantseveral possibleTherapy intentioncurativecurative or palliativepalliativeRisksAbdominal PainAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityColitisConstipationCystitisDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHepatotoxicityHyperbilirubinemiaHyperglycemiaHypertensionHyperthyroidismHypoalbuminemiaHypokalemiaHyponatremiaHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesIncrease Creatinine PhosphokinaseInfectionsLeukopeniaMucositisMyalgiasNauseaNeuropathyNeutropeniaOral MucositisPainPneumonitisPruritusPyrexiaRashRenal failure!Thrombocytopenia below 50 000/µlThromboembolic EventVisual DisturbancesVomiting only studiesPublicationAuthorAgulnik MAntman KBitz UBui NBusea JChen APChugh RDavis EDefachelles ASDemetri GDDickson MGarcıá-del-Muro XGounder MMGrobmyer SRGronchi AGrünwald VHensley MLJudson IKoscielniak E, Klingebiel TMaki ROosterom ATPalassini EPark MSPautier PPenel NRutkowski PSanfilippo RScheinberg T Schöffski PStacchiotti STap WTreuner J. Koscielniak Evan der Graaf WTWilky BAZalupski MZucali PDiseaseAggressive Fibromatose (Desmoid), neu diagnostiziert oder rezidiviert, nicht operabel, ECOG 0-1Aggressive Fibromatose, lokal fortgeschrittenAlveoläres Weichteilsarkom, nicht resezierbar oder metastasiert, ab 2 JahreAngiosarkom, bis zu 2 Vortherapien, ECOG 0-1Angiosarkom oder epitheloides Hämangioendotheliom, bis zu 3 Vortherapien, ECOG 0-1Dermatofibrosarcoma protuberans, lokal fortgeschritten oder metastasiert, teilweise mit fibrosarcomatöser TransformationEntdifferenziertes Liposarkom, nach 2-5 Vortherapien, ECOG 0-1Entzündlicher Myofibroblastentumor (inflammatorischer Myofibroblastentumor), lokal fortgeschritten, inoperabel, ALK+Fortgeschrittener solitärer fibröser Tumor, ECOG 0-3fortgeschrittenes oder metastasiertes Leiomyosarkom/Liposarkom, Erstliniefortgeschrittenes oder metastasiertes Weichteilsarkom, Zweitlinie nach Anthrazyklin oder Ifosfamid oder Kontrainidikation, ECOG 0-2fortgeschrittenes Weichteilsarkom, ECOG 0-1fortschreitendes Weichteilsarkom nach anthrazyklinhaltiger Therapie, high-grade uterines Leiomyosarkom, FIGO I-IIIA, ECOG 0-1, adjuvantHochmalignes Weichteilsarkom (Grad 2-3), fortgeschritten oder metastasiert, ECOG 0-1, 18-60 JahreLeiomyosarkom, metastasiert oder lokal fortgeschritten, inoperabel, ErstlinieLiposarkom, entdifferenziert, metastasiert oder lokal fortgeschritten, ECOG 0-1, 18-75 J., max. 1 VortherapieLiposarkom oder Leiomyosarkom, nicht resektabel oder metastasiert, Rezidiv nach Anthrazyklin und Ifosfamid (in Kombi oder sequentiell), ECOG 0-1lokalisiertes Weichteilsarkom, Grad 3 oder 2 mit 50% Nekrosen, ECOG < 1metastasiertes oder fortgeschrittenes Angiosarkom, Rezidivtherapie, ECOG 0-2metastasiertes oder nicht-resezierbares Weichteilsarkom, ECOG 0-2metastasiertes Weichteilsarkom, 2.- 5.-Linie, ECOG 0-1metastasiertes Weichteilsarkom, Anthrazyklinnaiv, ECOG 0-2metastasiertes Weichteilsarkom, Erstliniemetastasiertes Weichteilsarkom, Erstlinie, über 60 Jahre, ECOG 0-2Myxoides Liposarkom (HG-MLPS) G3, ab 5cm Größe, cM0Neo/adjuvante Therapie des Weichteilsarkoms mit niederiger Hospitalisierungsrate, ECOG 0-1, T 2b, G2-3Neo/adjuvante Therapie des Weichteilsarkoms mit niedriger Hospitalisierungsrate, ECOG 0-1, T 2b, G2-3Rezidivierendes oder progressives Weichteilsarkom, ECOG 0-2, ab 10 JahrenSolitärer fibröser Tumor oder metastasiertes HämangioperizytomSporadische desmoide Fibromatose (aggressive Fibromatose)Weichteilsarkom, alveoläres WeichteilsarkomWeichteilsarkom, alveoläres Weichteilsarkom, ab 16 J., ECOG 0-1, ab ZweitlinieWeichteilsarkom, HRWeichteilsarkom, Kinder, Jugendliche und junge ErwachseneWeichteilsarkom, neoadjuvantWeichteilsarkom, rezidiviertWeichteilsarkom, Rezidiv oder metastasiertWeichteilsarkom, Rhabdomyosarkom, Leiomyosarkom, Erstlinie, ECOG 0-2Weichteilsarkom, SynovialsarkomWeichteilsarkom schnell fortschreitend, ECOG 0-2wiederkehrendes, lokal fortgeschrittenes oder metastasiertes Lipo-/ Leiomyosarkom, ECOG 0-2OriginCWS 2002 Protokoll der Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)Dana-Farber Cancer Institute, Boston, MADepartement de Cancerologie Generale, Unite de Biostatistiques, and Departement d’Imagerie Medicale, Centre Oscar Lambret, ANGIOTAX studyDepartment of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, BelgiumDepartment of Medical Oncology and Hematology, Istituto Clinico Humanitas, ItalyDepartment of Surgery, Cancer Medicine and Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ISG-STS 1001Division of Cancer Medicine, The University of Texas MD Anderson Cancer, USADivision of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, ChicagoDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United StatesDivision of Hematology/Onkology, University of Michigan, Ann Arbor, MI, United StatesEORTC Soft Tissue and Bone Sarcoma GroupEORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group; PALETTE StudieEuropean Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupFondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyFondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyFondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori, Milan, ItalyGesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), Studienprotokoll CWS-GuidanceHELIOS Klinikum Bad Saarow, Sarcoma Center Berlin-Brandenburg, Bad Saarow, GermanyHospital General de Asturias, Oviedo, Spain, E.O.R.T.C. Soft Tissue and Bone Sarcoma GroupINSERM U1015, Gustave Roussy, Universite Paris-Saclay, Villejuif, France, VIT-0910 trialInstitut Català d’Oncologia L’Hospitalet, a Spanish Group for Research on Sarcomas StudyInstitut Gustave-Roussy, Villejuif, France, LMS-04 trialIRCCS Fondazione Istituto Nazionale TumoriIstituto Nazionale Tumori, Milan, ItalyMaria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw PolandMedical School Hannover, Hannover, GermanyMemorial Sloan-Kettering Cancer Center, New York, SARC 005 trialMemorial Sloan-Kettering Cancer Center New York, NYMemorial Sloan Kettering Cancer Center, New York, USAMemorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, USAMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, SEAL trialNational Cancer Institute, BethesdaRoyal Marsden Hospital London, UK, EORTC Soft Tissue and Bone Sarcoma GroupSouthwest Oncology Group studyStanford Cancer Institute, Stanford, CA, USAThe Trabectedin Global Sarcoma Study GroupThe University of Texas MD Anderson Cancer Center, Houston, TexasUniversity Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium, EORTC trial 90101 CREATEUniversity of Miami Miller School of Medicine, Miami, FL, USAUniversity of Michigan, Ann Arbor, USAProtocols in Revision 54 protocols foundProtocols under revision.Atezolizumab 1200, Soft Tissue Sarcoma (PID2455)Bevacizumab 15, Soft Tissue Sarcoma (PID1826)Cabazitaxel 25, Soft Tissue Sarcoma (PID2172)Crizotinib 250, Soft Tissue Sarcoma (PID2047)Dacarbazine 1200, Soft Tissue Sarcoma (PID1211)Dacarbazine 300, Soft Tissue Sarcoma (PID1212)Doxorubicin 15 / Dacarbazine 250, Soft Tissue Sarcoma (PID1214)Doxorubicin 25 / Ifosfamide 2.5, Soft Tissue Sarcoma (PID506)Doxorubicin 25 / Ifosfamide 3, Soft Tissue Sarcoma neoadjuvant (PID2545)Doxorubicin 60 / Dacarbazine 750, Soft Tissue Sarcoma (PID1215)Doxorubicin 60 / Trabectedin 1.1, Soft Tissue Sarcoma (PID2210)Doxorubicin 60, Soft Tissue Sarcoma, adjuvant, Part B (PID1946)Doxorubicin 75 / Dacarbazine 400, Soft Tissue Sarcoma (PID1213)Doxorubicin 75 / Ifosfamide 2.5, Soft Tissue Sarcoma neo/adjuvant (PID575)Doxorubicin 75, Soft Tissue Sarcoma (PID507)Epirubicin 60 / Ifosfamide 3, Soft Tissue Sarcoma neoadjuvant (PID976)Eribulin 1.23, Lipo- and Leiomyosarcoma (PID826)Gemcitabine 1800 / Dacarbazine 500, Soft Tissue Sarcoma (PID1181)Gemcitabine 900 / Docetaxel 100, Soft Tissue Sarcoma (PID570)Gemcitabine 900 / Docetaxel 100, Soft Tissue Sarcoma neo/adjuvant (PID576)Gemcitabine 900 / Docetaxel 75 / Bevacizumab 15, Soft Tissue Sarcoma (PID573)Gemcitabine 900 / Docetaxel 75, Soft Tissue Sarcoma, adjuvant, part A (PID1945)Ifosfamide 3, Soft Tissue Sarcoma (PID509)Ifosfamide 7, Soft Tissue Sarcoma, neoadjuvant (PID2546)Imatinib 300, Soft Tissue Sarcoma (PID2044)Imatinib 400, Soft Tissue Sarcoma (PID2048)Methotrexate 30 / Vinblastine 6, Soft Tissue Sarcoma (PID2042)Methotrexate 50 / Vinorelbine 20, Soft Tissue Sarcoma (PID2043)Olaratumab 15 / Doxorubicin 75 - Olaratumab 15 maintenance, Soft Tissue Sarcoma (PID847)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 1 (PID845)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 2-4 (PID846)Olaratumab 15 / Doxorubicin 75, Soft Tissue Sarcoma, Cycle 5-8 (PID851)Paclitaxel 200 / Bevacizumab 15, Soft Tissue Sarcoma (PID1828)Paclitaxel 80, Soft Tissue Sarcoma (PID1207)Paclitaxel 90 / Bevacizumab 15, Soft Tissue Sarcoma (PID1827)PAED CWS guidance, Methotrexate 20 / Vinblastine 3, fibromatosis, aggressive (PID1315)PAED CWS-Guidance, VAC - Vincristine 1.5 / Dactinomycin 1.5 / Cyclophosphamide 20, fibromatosis, aggressive (PID1312)Pazopanib 800, Soft Tissue Sarcoma (PID511)Pazopanib 800, Soft Tissue Sarcoma, first-line (PID1665)Doxorubicin Pegylated Liposomal 50, Soft Tissue Sarcoma (PID1200)Pembrolizumab 200 / Axitinib 5, Soft Tissue Sarcoma (PID2460)Pembrolizumab 200, Soft Tissue Sarcoma (PID2461)Selinexor 60, Soft Tissue Sarcoma (PID2053)Sorafenib 400, Aggressive Fibromatosis (PID699)Sunitinib 37.5, Soft Tissue Sarcoma (PID2046)Temozolomide 150 / Bevacizumab 5, Soft Tissue Sarcoma (PID2045)Trabectedin 1.3, Soft Tissue Sarcoma, neoadjuvant (PID2544)Trabectedin 1.5, Soft Tissue Sarcoma (PID510)VAIA III Block 1 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID657)VAIA III Block 2 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID659)VAIA III Block 3,4,6 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID660)VAIA III Block 5,7,8,9 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID661)VIT (Temozolomide 125 / Vincristine 2 / Irinotecan 50), Soft Tissue Sarcoma, Cycle 1 (PID2255)VIT (Temozolomide 150 / Vincristine 2 / Irinotecan 50), Soft Tissue Sarcoma, Cycle 2-12 (PID2256)